Consensus BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 20/09/2024 am IST			5-day change	1st Jan Change
198.59 ^USD	+0.66%		+1.18%	+10.11%

18/09	JMP Securities Initiates BeiGene at Outperform With $288 Price Target	MT
17/09	BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma After Prior Chemotherapy	CI

Evolution of the Average Target: BeiGene, Ltd.

Evolution of the Target Price: BeiGene, Ltd.

Changes in Analyst Recommendations: BeiGene, Ltd.

b62a1c556184ac0fc69fd287.t1apL8FvC9lWeRlrtp5rUUmmCVob5TKWbMlkXAOC1Ag.hjHsSrYmau1lDSg-0qcpCQHwOy1JvXDwAIxVGVDTv171GtpargxiqD1Jcg~7d5b426c60f35a3becdca9b6e250e57e

Analysts' recommendations: BeiGene, Ltd.

JMP Securities Initiates BeiGene at Outperform With $288 Price Target	18/09	MT
Nomura Adjusts BeiGene Price Target to $266 From $248.41, Maintains Buy Rating	16/07	MT
Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy	16/07	MT
Beigene Insider Sold Shares Worth $445,070, According to a Recent SEC Filing	27/06	MT
BeiGene to Award Shares Worth $15 Million to 11 Directors	17/04	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	11/04	MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating	27/03	MT
Nomura Adjusts Beigene’s Price Target to HK$150.60 From HK$162.05, Keeps at Buy	22/02	MT
Nomura Adjusts BeiGene Price Target to $268.36 From $253.14, Maintains Buy Rating	07/11	MT
Citigroup Lowers Price Target on BeiGene to $285 From $290, Maintains Buy Rating	26/23/26	MT
Citigroup Raises BeiGene Price Target to $290 From $285, Maintains Buy Rating	20/23/20	MT
Macquarie Starts BeiGene at Outperform, $259 Price Target	12/23/12	MT
Morgan Stanley Adjusts BeiGene's Price Target to $319 From $321, Keeps Overweight Rating	29/23/29	MT
Jefferies Starts BeiGene at Buy With $287 Price Target	17/23/17	MT
JPMorgan Chase Adjusts Price Target on BeiGene to $300 From $297, Maintains Overweight Rating	07/23/07	MT
Nomura Adjusts BeiGene Price Target to $253.14 From $309.47, Maintains Buy Rating	20/23/20	MT
Nomura Adjusts BeiGene's Price Target to HK$152.86 From HK$186.87, Keeps at Buy	20/23/20	MT
Citigroup Initiates BeiGene With Buy Rating, $275 Price Target	17/23/17	MT
Bernstein Downgrades BeiGene to Market Perform From Outperform, Cuts Price Target to $196 From $335	30/23/30	MT
Nomura Adjusts BeiGene's Price Target to HK$186.87 From HK$172.81, Keeps at Buy	05/23/05	MT
Nomura Adjusts BeiGene Price Target to $309.47 From $286.19, Maintains Buy Rating	05/23/05	MT
Morgan Stanley Adjusts Price Target on BeiGene to $321 From $325, Maintains Overweight Rating	28/23/28	MT
Cowen Adjusts Price Target on BeiGene to $262 From $213, Maintains Outperform Rating	28/23/28	MT
Nomura Adjusts BeiGene's Price Target to $286.19 From $281.78, Maintains Buy Rating	23/23/23	MT
Nomura Adjusts BeiGene's Price Target to HK$172.81 From HK$170.15, Keeps at Buy	23/23/23	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	BEIGENE, LTD.					+38.71%
	VERTEX PHARMACEUTICALS INCORPORATED					+7.52%
	REGENERON PHARMACEUTICALS, INC.					+2.05%
	ARGENX SE					+7.37%
	BIONTECH SE					+4.80%
	SUMMIT THERAPEUTICS INC.					+20.86%
	GENMAB A/S					+36.97%
	WUXI APPTEC CO., LTD.					+46.16%
	VAXCYTE, INC.					+24.42%
	INSMED INCORPORATED					+20.08%
	Average					+20.89%
	Weighted average by Cap.					+11.59%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

198.59USD

Average target price

273.64USD

Spread / Average Target

+37.79%

High Price Target

345.00USD

Spread / Highest target

+73.72%

Low Price Target

152.00USD

Spread / Lowest Target

-23.46%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

JMP Securities
Nomura
Bernstein
Citigroup
Macquarie
Morgan Stanley
Jefferies & Co.
JPMorgan Chase
Cowen
Guggenheim
SVB Securities LLC
CMB International
SVB Leerink
Goldman Sachs
HSBC
China Renaissance
CLSA